Investment Advisory Services Inc. TX ADV Sells 113 Shares of Zoetis Inc. (NYSE:ZTS)

Investment Advisory Services Inc. TX ADV reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,755 shares of the company’s stock after selling 113 shares during the quarter. Investment Advisory Services Inc. TX ADV’s holdings in Zoetis were worth $1,101,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. AMF Tjanstepension AB raised its stake in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares in the last quarter. CWM LLC raised its stake in Zoetis by 1.8% in the third quarter. CWM LLC now owns 19,330 shares of the company’s stock valued at $3,777,000 after buying an additional 339 shares during the period. Wedmont Private Capital boosted its stake in shares of Zoetis by 15.1% during the 3rd quarter. Wedmont Private Capital now owns 2,958 shares of the company’s stock worth $554,000 after acquiring an additional 388 shares during the period. LVW Advisors LLC raised its stake in Zoetis by 11.8% in the 3rd quarter. LVW Advisors LLC now owns 1,470 shares of the company’s stock valued at $287,000 after acquiring an additional 155 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Zoetis by 307.5% during the third quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,930 shares of the company’s stock worth $572,000 after purchasing an additional 2,211 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research analyst reports. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Stifel Nicolaus decreased their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Finally, Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $215.00.

Zoetis Trading Down 1.6 %

ZTS opened at $171.37 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a fifty day moving average of $169.26 and a 200-day moving average of $179.22. The stock has a market cap of $77.32 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s payout ratio is 37.59%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.